益佰制药(600594) - 2025 Q4 - 年度业绩预告

Financial Performance Expectations - Guizhou Yibai Pharmaceutical Co., Ltd. expects a net profit attributable to shareholders to be negative for the fiscal year 2025, indicating an anticipated loss[1] - Final financial data will be based on the officially disclosed audited annual report for 2025[1] Compliance and Reporting - The company is accelerating its financial accounting processes to comply with the Shanghai Stock Exchange regulations and will disclose the 2025 performance forecast within the stipulated timeframe[1]